Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

TOKYO, Jan 6, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has entered into a License Agreement granting the…